Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Circio Holding

Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti

Vain PDF

118 päivää sitten

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 9 t sitten
    ·
    What can one look forward to in the Q2 report on August 31?
    8 t sitten
    ·
    Info about the financial situation
  • 11 t sitten
    ·
    Talented people deserve a stage. Tekinvestor. "One more thing: no one else has managed what Circio is doing with its circVec. Just so that's clear. Wiklund has said that at some point an actor might emerge who solves what they do in a similar way, but that it will take many years before anyone is close. And by then, Circio will hopefully be clinically validated and absolutely market-leading within circRNA. It was also CTO Birkeballe and CEO Wiklund who gave the molecule the name circRNA back in 2012, when they were the first in the world to discover that circRNA has an important function in human cells. Birkeballe is literally "the founding father" of a field that many players are now investing in and where several billion-class transactions have recently been made. Everyone who studies circRNA, and everyone who develops therapeutic methods with circRNA, relies on Birkeballe's research. One can in many ways say that Circio IS circRNA."
  • 11 t sitten · Muokattu
    ·
    This can surely be repeated so that any new ones are updated. Timeline autumn 2026 Circio. When can info/news come? Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations. Preclinical data in H2 2026 (Important) * In vivo CAR-T-data. * Efficacy data within wet AMD (eye treatment). * Heart disease model. * CNS proof-of-concept from the ongoing big pharma partner. This is considered by analysts as the most value-creating triggers towards a possible licensing agreement. Extraordinary General Meeting – August 25 * Election of Dinah Sah to the board. * Will strengthen the company's industrial profile. * October Publication of the ESGCT abstract with full data. October ESGCT oral presentation * Circio presents the circVec platform in front of a large international audience of pharmaceutical companies and potential partners. When? The most likely timeline is: * August 2026 * Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations can come at any time. * September 2026 * The first preclinical data are expected: * In vivo CAR-T * Wet AMD * Heart disease model * CNS proof-of-concept from the big pharma collaboration Analysts point to these as the most important value drivers towards a first licensing agreement. The next 2–3 months could be very news-rich. The trigger the market is probably waiting for most is the first strong preclinical efficacy data, especially within in vivo CAR-T and the CNS program, since positive results can lay the foundation for a licensing or partnership agreement and an update on Big Pharma collaboration.
    11 t sitten
    ·
    Who do you think Big Pharma is?
  • 16 t sitten
    ·
    Difficult to break the 9 level here. Probably needs some news.
    15 t sitten
    ·
    I doubt that everyone here will hold out for three years. Then one must ration one's strength.
  • 15 t sitten · Muokattu
    ·
    There it crashed, yes! Within one minute, the price really plunged. Perhaps someone put out a large block at the price the market is willing to give, and then it quickly goes the wrong way!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

118 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 9 t sitten
    ·
    What can one look forward to in the Q2 report on August 31?
    8 t sitten
    ·
    Info about the financial situation
  • 11 t sitten
    ·
    Talented people deserve a stage. Tekinvestor. "One more thing: no one else has managed what Circio is doing with its circVec. Just so that's clear. Wiklund has said that at some point an actor might emerge who solves what they do in a similar way, but that it will take many years before anyone is close. And by then, Circio will hopefully be clinically validated and absolutely market-leading within circRNA. It was also CTO Birkeballe and CEO Wiklund who gave the molecule the name circRNA back in 2012, when they were the first in the world to discover that circRNA has an important function in human cells. Birkeballe is literally "the founding father" of a field that many players are now investing in and where several billion-class transactions have recently been made. Everyone who studies circRNA, and everyone who develops therapeutic methods with circRNA, relies on Birkeballe's research. One can in many ways say that Circio IS circRNA."
  • 11 t sitten · Muokattu
    ·
    This can surely be repeated so that any new ones are updated. Timeline autumn 2026 Circio. When can info/news come? Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations. Preclinical data in H2 2026 (Important) * In vivo CAR-T-data. * Efficacy data within wet AMD (eye treatment). * Heart disease model. * CNS proof-of-concept from the ongoing big pharma partner. This is considered by analysts as the most value-creating triggers towards a possible licensing agreement. Extraordinary General Meeting – August 25 * Election of Dinah Sah to the board. * Will strengthen the company's industrial profile. * October Publication of the ESGCT abstract with full data. October ESGCT oral presentation * Circio presents the circVec platform in front of a large international audience of pharmaceutical companies and potential partners. When? The most likely timeline is: * August 2026 * Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations can come at any time. * September 2026 * The first preclinical data are expected: * In vivo CAR-T * Wet AMD * Heart disease model * CNS proof-of-concept from the big pharma collaboration Analysts point to these as the most important value drivers towards a first licensing agreement. The next 2–3 months could be very news-rich. The trigger the market is probably waiting for most is the first strong preclinical efficacy data, especially within in vivo CAR-T and the CNS program, since positive results can lay the foundation for a licensing or partnership agreement and an update on Big Pharma collaboration.
    11 t sitten
    ·
    Who do you think Big Pharma is?
  • 16 t sitten
    ·
    Difficult to break the 9 level here. Probably needs some news.
    15 t sitten
    ·
    I doubt that everyone here will hold out for three years. Then one must ration one's strength.
  • 15 t sitten · Muokattu
    ·
    There it crashed, yes! Within one minute, the price really plunged. Perhaps someone put out a large block at the price the market is willing to give, and then it quickly goes the wrong way!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

118 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 9 t sitten
    ·
    What can one look forward to in the Q2 report on August 31?
    8 t sitten
    ·
    Info about the financial situation
  • 11 t sitten
    ·
    Talented people deserve a stage. Tekinvestor. "One more thing: no one else has managed what Circio is doing with its circVec. Just so that's clear. Wiklund has said that at some point an actor might emerge who solves what they do in a similar way, but that it will take many years before anyone is close. And by then, Circio will hopefully be clinically validated and absolutely market-leading within circRNA. It was also CTO Birkeballe and CEO Wiklund who gave the molecule the name circRNA back in 2012, when they were the first in the world to discover that circRNA has an important function in human cells. Birkeballe is literally "the founding father" of a field that many players are now investing in and where several billion-class transactions have recently been made. Everyone who studies circRNA, and everyone who develops therapeutic methods with circRNA, relies on Birkeballe's research. One can in many ways say that Circio IS circRNA."
  • 11 t sitten · Muokattu
    ·
    This can surely be repeated so that any new ones are updated. Timeline autumn 2026 Circio. When can info/news come? Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations. Preclinical data in H2 2026 (Important) * In vivo CAR-T-data. * Efficacy data within wet AMD (eye treatment). * Heart disease model. * CNS proof-of-concept from the ongoing big pharma partner. This is considered by analysts as the most value-creating triggers towards a possible licensing agreement. Extraordinary General Meeting – August 25 * Election of Dinah Sah to the board. * Will strengthen the company's industrial profile. * October Publication of the ESGCT abstract with full data. October ESGCT oral presentation * Circio presents the circVec platform in front of a large international audience of pharmaceutical companies and potential partners. When? The most likely timeline is: * August 2026 * Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations can come at any time. * September 2026 * The first preclinical data are expected: * In vivo CAR-T * Wet AMD * Heart disease model * CNS proof-of-concept from the big pharma collaboration Analysts point to these as the most important value drivers towards a first licensing agreement. The next 2–3 months could be very news-rich. The trigger the market is probably waiting for most is the first strong preclinical efficacy data, especially within in vivo CAR-T and the CNS program, since positive results can lay the foundation for a licensing or partnership agreement and an update on Big Pharma collaboration.
    11 t sitten
    ·
    Who do you think Big Pharma is?
  • 16 t sitten
    ·
    Difficult to break the 9 level here. Probably needs some news.
    15 t sitten
    ·
    I doubt that everyone here will hold out for three years. Then one must ration one's strength.
  • 15 t sitten · Muokattu
    ·
    There it crashed, yes! Within one minute, the price really plunged. Perhaps someone put out a large block at the price the market is willing to give, and then it quickly goes the wrong way!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt